2023
Dietary Patterns Among Individuals with Plasma Cell Disorders Compared to the General US Population
Traore K, Taneja A, Gorshein E, Castro F, Derkach A, Martinez J, Serrano E, Lesokhin A, Ahlstrom J, Block T, Hydren J, Usmani S, Shah U. Dietary Patterns Among Individuals with Plasma Cell Disorders Compared to the General US Population. Blood 2023, 142: 7363. DOI: 10.1182/blood-2023-186913.Peer-Reviewed Original ResearchBody mass indexPlasma cell disordersHigher HEI scoresFood frequency questionnaireGeneral US populationHEI scoresDietary patternsTotal fruit consumptionMultiple myelomaUS populationDietary interventionDietary guidelinesFruit consumptionCell disordersHealthy dietBlock Food Frequency QuestionnaireElevated body mass indexLower body mass indexCancer-specific mortalityLong-term outcomesHealthy Eating IndexNutrition Examination SurveyHealthy dietary habitsRole of nutritionOlder age groups
2021
Outcomes Among Primary Refractory Multiple Myeloma Patients in the Era of Monoclonal Antibodies: The Yale Experience
Liu Y, Kywe B, Crawford L, Lora F, Bar N, Browning S, Gorshein E, Parker T, Neparidze N. Outcomes Among Primary Refractory Multiple Myeloma Patients in the Era of Monoclonal Antibodies: The Yale Experience. Blood 2021, 138: 1635. DOI: 10.1182/blood-2021-146619.Peer-Reviewed Original ResearchAutologous stem cell transplantMedian overall survivalInternational Staging System stage IIRefractory multiple myeloma patientsOverall survivalMultiple myeloma patientsMultiple myelomaInduction therapyPartial responsePrimary refractoryInduction regimenMyeloma patientsMonoclonal antibodiesPlasma cellsInternational Myeloma Working Group criteriaYale New Haven Health SystemStage IIHigh-risk cytogeneticsGood partial responseRetrospective cohort studyMajority of patientsMRD-negative statusMonoclonal antibody therapyStem cell transplantImportant prognostic valueUse of Denosumab after Zoledronic Acid in Patients with Multiple Myeloma: Real-World Experience from 2015 to 2019 at Yale Cancer Center
Dosani T, Poteraj A, Parker T, Bar N, Browning S, Gorshein E, Anderson T, Insogna K, Neparidze N. Use of Denosumab after Zoledronic Acid in Patients with Multiple Myeloma: Real-World Experience from 2015 to 2019 at Yale Cancer Center. Blood 2021, 138: 4756. DOI: 10.1182/blood-2021-147466.Peer-Reviewed Original ResearchBone-modifying agentsUse of denosumabYale Cancer CenterZoledronic acidMultiple myelomaMM patientsCancer CenterMedian numberPhysician preferenceCommon reasonClinical practiceNew fracturesNuclear factor kappa-B ligandStudy periodApproval of denosumabEfficacy of denosumabIncidence of SREsMain treatment centreSmilow Cancer HospitalSuppress bone turnoverPatient's renal functionBone resorption markersCohort of patientsGlomerular filtration rateDate of diagnosis